"We continued to deliver on our planned progress in all of Neovasc's programs during the second quarter," commented Alexei Marko, chief executive officer of Neovasc. "We reported strong growth in our contract manufacturing and consulting services businesses as we prepared for our planned exit from surgical tissue patch products, a lower margin line we sold to LeMaitre Vascular last year.